Schmitt M - Search Results

1

Hofer S, Mengele K, Stemmler HJ, Schmitt M, Pestalozzi B. Hofer S, et al. Among authors: schmitt m. Acta Oncol. 2012 Sep;51(7):955-6. doi: 10.3109/0284186X.2012.673736. Epub 2012 Apr 23. Acta Oncol. 2012. PMID: 22524214 No abstract available.

2

Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.

Stemmler HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Herrmann KA, Schaffer P, Heinemann V. Stemmler HJ, et al. Among authors: schmitt m. Anticancer Drugs. 2008 Sep;19(8):832-6. doi: 10.1097/CAD.0b013e32830b58b0. Anticancer Drugs. 2008. PMID: 18690096

3

Emerging biomarkers in breast cancer care.

Napieralski R, Brünner N, Mengele K, Schmitt M. Napieralski R, et al. Among authors: schmitt m. Biomark Med. 2010 Aug;4(4):505-22. doi: 10.2217/bmm.10.73. Biomark Med. 2010. PMID: 20701440 Review.

4

Complement activation and rituximab distribution in CNS NHL--letter.

Hofer S, Mengele K, Schmitt M, Pestalozzi B, Aebi S. Hofer S, et al. Among authors: schmitt m. Clin Cancer Res. 2015 Jan 15;21(2):490. doi: 10.1158/1078-0432.CCR-14-0939. Clin Cancer Res. 2015. PMID: 25593346 Free article. No abstract available.

5

Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.

Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lässig D, Schoenberg S, Heinemann V. Stemmler HJ, et al. Among authors: schmitt m. Oncol Rep. 2006 May;15(5):1373-7. doi: 10.3892/or.15.5.1373. Oncol Rep. 2006. PMID: 16596213

6

Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.

Ludyga N, Anastasov N, Rosemann M, Seiler J, Lohmann N, Braselmann H, Mengele K, Schmitt M, Höfler H, Aubele M. Ludyga N, et al. Among authors: schmitt m. Mol Cancer Res. 2013 Apr;11(4):381-92. doi: 10.1158/1541-7786.MCR-12-0378. Epub 2013 Jan 30. Mol Cancer Res. 2013. PMID: 23364537

7

Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.

Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer HD, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba C, Nitz U, Harbeck N. Gluz O, et al. Among authors: schmitt m. J Clin Oncol. 2009 Dec 20;27(36):6144-51. doi: 10.1200/JCO.2008.19.6261. Epub 2009 Nov 9. J Clin Oncol. 2009. PMID: 19901122 Clinical Trial.

8

Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N. Schmitt M, et al. Expert Rev Mol Diagn. 2010 Nov;10(8):1051-67. doi: 10.1586/erm.10.71. Expert Rev Mol Diagn. 2010. PMID: 21080821 Review.

9

Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer.

Dorn J, Gkazepis A, Kotzsch M, Kremer M, Propping C, Mayer K, Mengele K, Diamandis EP, Kiechle M, Magdolen V, Schmitt M. Dorn J, et al. Among authors: schmitt m. Biol Chem. 2014 Jan;395(1):95-107. doi: 10.1515/hsz-2013-0172. Biol Chem. 2014. PMID: 23999494

10

Ex vivo detection of apoptotic trophoblast cells applying flow cytofluorometry and immunocytochemistry using M30 antibody directed to the cytokeratin 18 neo-epitope.

Krol J, Mengele K, Ottl-Mantchenko I, Welk A, Wasilewitsch I, von Steinburg SP, Schneider KT, Schmitt M. Krol J, et al. Among authors: schmitt m. Int J Mol Med. 2005 Sep;16(3):415-20. Int J Mol Med. 2005. PMID: 16077948

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,923 results

Search Page